Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories, Inc. insider trust reports share conversion and charitable gift. On February 11, 2026, the Dagmar Dolby Trust converted 380,000 shares of Class B Common Stock into 380,000 shares of Class A Common Stock at no cost to the holder. Immediately afterward, the trust made a bona fide gift of all 380,000 Class A shares to an unaffiliated charitable organization, leaving that trust with no Class A shares from this transaction. The filing also lists large remaining indirect holdings of convertible Class B Common Stock across several Dolby family trusts and LLCs, all of which are convertible into Class A on a 1‑for‑1 basis.
Dolby Laboratories has a holder planning to sell 2,667 shares of its common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $177,022.66 and 60,884,768 shares outstanding.
The shares come from a stock option exercise dated February 13, 2026, paid in cash on the same date. The person for whose account the shares will be sold represents that they are not aware of any undisclosed material adverse information about Dolby’s current or prospective operations.
Morgan Stanley, Atlanta Capital Management, and Eaton Vance Atlanta Capital SMID-Cap Fund filed an amended Schedule 13G reporting significant holdings of Dolby Laboratories, Inc. Class A common stock.
Morgan Stanley reports beneficial ownership of 6,192,241 shares, or 10.2% of the class. Atlanta Capital reports 5,226,244 shares, or 8.6%, and the Eaton Vance Atlanta Capital SMID-Cap Fund reports 3,965,479 shares, or 6.5%. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Dolby.
Dolby Laboratories President and CEO Kevin J. Yeaman, who is also a director, reported an internal transfer of employee stock options rather than a market trade. On February 5, 2026, an option covering 145,252 shares of Dolby Class A common stock with a $66.62 exercise price was moved from his direct ownership to the Kevin and Rachel Yeaman Family Trust, a revocable trust, for no consideration.
The filing notes this change was made for estate planning purposes and is exempt from Section 16(b) under Rule 16b‑5. The option was originally granted for 145,252 shares, with one-quarter vesting on the first anniversary of December 15, 2025 and the remaining shares vesting in equal monthly installments over the subsequent 36 months, and it expires on December 15, 2035.
Dolby Laboratories, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on February 3, 2026 via live webcast. Holders of Class A and Class B common stock, which carry one vote and ten votes per share respectively, voted together as a single class on all items.
All eight director nominees, including Kevin Yeaman, David Dolby, and others, were elected, each receiving over 384 million votes for, with broker non-votes of 3,884,937 on each director proposal. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 396,794,929 votes for and 2,216,964 against.
In addition, stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 25, 2026, with 400,209,219 votes for and 2,718,973 against. Overall, the meeting confirmed the existing board slate, executive pay program, and external auditor.
Dolby Laboratories director Simon Segars received an equity award of 3,908 restricted stock units of Class A common stock on 02/03/2026 under the company’s 2020 Stock Plan at a grant price of $0 per share. Each unit represents one share of Class A common stock upon vesting.
The units vest on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual shareholders meeting, as long as Segars continues serving on the board. After this grant, he beneficially owns 47,150 Class A shares, including 3,908 unvested RSUs that remain subject to forfeiture until they vest.
Dolby Laboratories director and 10% owner David Dolby received an equity award of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026. The RSUs were granted at a price of $0 per unit under the company’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one share of Class A common stock that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholders’ meeting, as long as he continues to serve on the board. After this award, he beneficially owns 92,718 Class A shares, including the 3,908 unvested RSU shares that are subject to forfeiture until they vest.
Dolby Laboratories director Emily Rollins received an equity grant as part of her board compensation. On February 3, 2026, she was awarded 3,908 restricted stock units of Class A common stock at a price of $0 per share under Dolby’s 2020 Stock Plan.
Each unit represents one share that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she beneficially owns 13,541 Class A shares, including the unvested units, which remain subject to forfeiture until they vest.
Dolby Laboratories director Peter C. Gotcher received an equity award of 3,908 restricted stock units (RSUs) of Class A Common Stock on February 3, 2026. The RSUs were granted at a price of $0 under Dolby’s 2020 Stock Plan.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. Vesting occurs on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if Gotcher continues serving on the board.
After this grant, Gotcher beneficially owns 44,641 shares of Class A Common Stock, including 3,908 shares underlying unvested RSUs that are subject to forfeiture until they vest.
Dolby Laboratories director Anjali Sud reported a grant of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026 at a price of $0. The award was made under Dolby’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one Dolby Class A share that vests on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if she continues serving on the board. After this grant, she beneficially owns 16,079 Class A shares, including 3,908 unvested RSU-based shares that remain subject to forfeiture until they vest.